Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
OpenAI Rejects Apple Trade Secret Theft Claims 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Street Poller Media and The Boom of the Street Interview Ad Industry 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Add as a preferred source on Google
AUSTIN, Texas, March 20, 2018 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present a corporate update at the 17th Annual Needham Healthcare Conference in New York on Tuesday, March 27 at 9:00 a.m. ET.
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
[email protected]
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
[email protected]
